MicroPort CardioFlow Accelerates Global TAVI Expansion with Strong 2025 Growth Outlook

The latest update is out from MicroPort CardioFlow Medtech Corp. ( (HK:2160) ).

MicroPort CardioFlow Medtech Corporation announced that its VitaFlow series TAVI systems have now been introduced in 35 countries and regions, with cumulative implantations nearing 1,300 cases. The company expects implantation volume in 2025 to exceed 850 procedures, implying a year-on-year increase of almost 350%, and reported that second-half 2025 volumes grew by more than 170% versus the first half, driven by CE-mark-backed expansion of VitaFlow Liberty in Europe and rising adoption in emerging Asian and Latin American markets. Management believes the recent acquisition of MicroPort Cardiac Rhythm Management Limited will bolster local distribution channels and clinical support in mature markets like Europe, improving market access and deepening penetration for its TAVI products; the group plans to leverage these integration synergies to develop next-generation TAVI devices, broaden its structural heart disease solutions, and strengthen competitiveness in global valve therapy.

The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.

More about MicroPort CardioFlow Medtech Corp.

MicroPort CardioFlow Medtech Corporation is a medical device company focused on structural heart disease, specializing in transcatheter aortic valve implantation (TAVI) systems under its VitaFlow series. The group targets global markets, including mature regions such as Europe and emerging markets across Asia and Latin America, positioning itself within the broader global valve therapy and cardiovascular intervention landscape.

Average Trading Volume: 4,607,838

Technical Sentiment Signal: Sell

Current Market Cap: HK$6.3B

Learn more about 2160 stock on TipRanks’ Stock Analysis page.